Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai

Ensysce Biosciences President James Morrison participated in the Family Office Summit in Dubai on October 15, 2026, as part of a global investor and strategic outreach initiative. The company recapped that in September 2026 it submitted a Phase 2a protocol for CY200, its CRPS candidate with FDA Orphan Drug Designation, to the UK MHRA, following the August 2026 acquisition of Cy Biopharma.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.